^
    Back
    Association details:
    Biomarker:AXL positive
    Cancer:Non Small Cell Lung Cancer
    Drug:bemcentinib (BGB324) (AXL inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    PRNewswire
    Title:

    BerGenBio Receives FDA Fast Track Designation For Bemcentinib / Anti-PD-(L)1 Combination In NSCLC

    Published date:
    06/08/2021
    Excerpt:
    BerGenBio ASA ...today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Bemcentinib in combination with an anti-PD-(L)1 agent for the treatment of patients with AXL-positive advanced/metastatic non-small cell lung cancer (NSCLC).
    Secondary therapy:
    PD-L1 inhibitor